In the News

Barclays: ‘New Advances in the Biology of Aging’

Jim Mellon, Chairman of Juvenescence, speaks with Barclays as part of the ‘Beyond 100’ program, about the science of longevity and the implications of living until 120 years.

Barclays: ‘New Advances in the Biology of Aging’

Jim Mellon, Chairman of Juvenescence, speaks with Barclays as part of the ‘Beyond 100’ program, about the science of longevity and the implications of living until 120 years.

Longevity Technology: 'Juvenescence CEO on near...

Dr. Greg Bailey, MD gives an interview to Longevity Technology on near-term longevity breakthroughs, including the latest developments at Juvenescence and dealing with the impact of COVID-19.   

Longevity Technology: 'Juvenescence CEO on near...

Dr. Greg Bailey, MD gives an interview to Longevity Technology on near-term longevity breakthroughs, including the latest developments at Juvenescence and dealing with the impact of COVID-19.   

Longevity Technology: ‘Relation-Mila collaborat...

Relation Therapeutics and Mila, the Montreal-based AI research institute are collaborating on a new project targeting the development of COVID-19 therapeutics funded by the Bill & Melinda Gates Foundation.   

Longevity Technology: ‘Relation-Mila collaborat...

Relation Therapeutics and Mila, the Montreal-based AI research institute are collaborating on a new project targeting the development of COVID-19 therapeutics funded by the Bill & Melinda Gates Foundation.   

Longevity Technology: 'Hufford interview: "It’s...

LyGenesis CEO Michael Hufford talks to Longevity Technology about Longevity research programs and investment.

Longevity Technology: 'Hufford interview: "It’s...

LyGenesis CEO Michael Hufford talks to Longevity Technology about Longevity research programs and investment.

Hill Dickinson: Interview with Colin Watts, Juv...

MDI’s expertise will help fight coronary heart disease, thrombosis, and chronic fibrotic and inflammatory diseases.

Hill Dickinson: Interview with Colin Watts, Juv...

MDI’s expertise will help fight coronary heart disease, thrombosis, and chronic fibrotic and inflammatory diseases.

Longevity Technology: Equity investment in MDI ...

MDI’s expertise will help fight coronary heart disease, thrombosis, and chronic fibrotic and inflammatory diseases.

Longevity Technology: Equity investment in MDI ...

MDI’s expertise will help fight coronary heart disease, thrombosis, and chronic fibrotic and inflammatory diseases.